Abstract
Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.
| Original language | English |
|---|---|
| Pages (from-to) | 541-547 |
| Number of pages | 7 |
| Journal | Pharmacological Research |
| Volume | 47 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2003 |
Fingerprint
Keywords
- Allergic rhinitis
- Bronchial asthma
- Leukotriene receptor antagonists
- Mucociliary clearance
- Nasal cytology
- Zafirlukast
ASJC Scopus subject areas
- Pharmacology
Cite this
Effects of zafirlukast on bronchial asthma and allergic rhinitis. / Piatti, G.; Ceriotti, L.; Cavallaro, G.; Ambrosetti, U.; Mantovani, M.; Pistone, A.; Centanni, S.
In: Pharmacological Research, Vol. 47, No. 6, 01.06.2003, p. 541-547.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of zafirlukast on bronchial asthma and allergic rhinitis
AU - Piatti, G.
AU - Ceriotti, L.
AU - Cavallaro, G.
AU - Ambrosetti, U.
AU - Mantovani, M.
AU - Pistone, A.
AU - Centanni, S.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.
AB - Asthma and allergic rhinitis are common conditions, occurring with increasing prevalence and frequently coexist. In both conditions histamine and cysteinil leukotrienes are important pathogenic inflammatory mediators. We evaluated the effects of the leukotriene receptor antagonist zafirlukast, 20mg administered twice daily for 2 weeks, in patients with allergic rhinitis and bronchial asthma during the grass pollen season. Patients underwent skin prick testing, spirometry, rhinomanometry, mucus transport test with saccharine, nasal epithelial brushing to study ciliary beat and, finally, nasal lavage. Thirty-five subjects completed the study. At the end of the study period, zafirlukast significantly reduced asthma and rhinitis symptoms (P≤0.05); FEV 1 values were unchanged (P=0.10), whereas nasal resistances showed a decrease following treatment (P=0.01). Ciliary beat frequency (CBF) also improved (P=0.00), although mucociliary transport showed no improvement (P=0.87). The number of eosinophils in nasal lavage fluid decreased (P=0.00) while that of neutrophils was unchanged (P=0.09). These positive effects suggest that zafirlukast may be usefully employed in the treatment of both bronchial asthma, as previously demonstrated, and allergic rhinitis.
KW - Allergic rhinitis
KW - Bronchial asthma
KW - Leukotriene receptor antagonists
KW - Mucociliary clearance
KW - Nasal cytology
KW - Zafirlukast
UR - http://www.scopus.com/inward/record.url?scp=0038639212&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038639212&partnerID=8YFLogxK
U2 - 10.1016/S1043-6618(03)00017-3
DO - 10.1016/S1043-6618(03)00017-3
M3 - Article
C2 - 12742009
AN - SCOPUS:0038639212
VL - 47
SP - 541
EP - 547
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
IS - 6
ER -